DEF: 4D Molecular Therapeutics Announces 2025 Annual Meeting of Stockholders

4D Molecular Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, auditor ratification, executive compensation, and say-on-pay frequency.

Summary

• 4D Molecular Therapeutics (4DMT) has announced its 2025 Annual Meeting of Stockholders, which will be held virtually on June 17, 2025, at 8:30 a.m. Pacific time.
• Stockholders of record as of April 21, 2025, are eligible to vote.
• The meeting will address the election of three Class II directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, an advisory vote on executive compensation (say-on-pay), and an advisory vote on the frequency of future say-on-pay votes.
• The Board of Directors recommends voting FOR the election of director nominees, FOR the ratification of PricewaterhouseCoopers LLP, FOR the compensation of named executive officers, and ONE YEAR for the frequency of future say-on-pay votes.
• The company had 46,324,642 shares of common stock outstanding as of the record date, excluding 9,385,000 shares issuable upon the exercise of pre-funded warrants.
• The proxy materials were first made available on or about April 29, 2025.
• The company's board consists of seven directors divided into three classes with staggered three-year terms.
• The company's non-employee directors received an annual cash retainer of $40,000 in 2024, with additional compensation for committee chairs and members.
• The Executive Chairman received an annual retainer of $150,000 in 2024.
• The company's compensation committee retained Radford, an executive compensation consulting firm, to provide advice on executive compensation matters.
• The company has adopted a compensation recovery (clawback) policy as required by Rule 10D-1 under the Exchange Act.
• The company maintains a 401(k) retirement savings plan for its employees, including NEOs, with matching contributions.
• The company has entered into change in control severance agreements with each NEO, providing for severance benefits in the event of termination or resignation under certain circumstances.
• The company's largest stockholders include RA Capital Management, L.P. (9.99%), Biotechnology Value Fund, L.P. (9.99%), The Goldman Sachs Group, Inc. (9.6%), BlackRock, Inc. (7.8%), Venrock Healthcare Capital Partners III, L.P. (6.4%), and The Vanguard Group (6.0%).

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting standard corporate governance matters. The recommendations of the board are clear and straightforward, suggesting a stable and well-managed company. The sentiment is slightly positive due to the routine nature of the announcements and the absence of any significant negative information.

Positives

• The company is adhering to good corporate governance practices by holding an annual meeting and seeking stockholder input on key decisions.
• The Board is providing clear recommendations on how stockholders should vote on each proposal.
• The company has a compensation recovery (clawback) policy in place, which is a positive governance feature.
• The company offers a 401(k) plan with matching contributions and health and welfare benefits to employees, which can help attract and retain talent.
• The company has change in control severance agreements with NEOs, providing clarity and potential stability during transitions.

Negatives

• The proxy statement does not explicitly address any specific negative aspects of the company's performance or governance.
• The document focuses on procedural matters related to the annual meeting rather than highlighting any challenges or areas for improvement within the company.

Risks

• The advisory vote on executive compensation could result in negative feedback from stockholders if they are not satisfied with the compensation levels.
• The company's reliance on key personnel, particularly executive officers, could pose a risk if there are unexpected departures.
• The company's business is subject to various risks, including those related to clinical trials, regulatory approvals, and competition, which are not explicitly detailed in this proxy statement but are inherent in the biotechnology industry.

Future Outlook

The Board intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for its 2026 annual meeting.

Industry Context

As a biotechnology company, 4D Molecular Therapeutics operates in a highly competitive and regulated industry. The matters discussed in the proxy statement, such as executive compensation and corporate governance, are standard topics for publicly traded companies in this sector. The virtual format of the annual meeting reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is generally in line with industry practices for similarly sized biotechnology companies.
• The use of an independent compensation consultant (Radford) is a common practice to ensure that executive compensation is aligned with market rates and performance.
• The adoption of a clawback policy is consistent with regulatory requirements and reflects a commitment to responsible corporate governance.
• The company's largest stockholders include institutional investors such as RA Capital Management, Biotechnology Value Fund, BlackRock, and The Vanguard Group, which is typical for publicly traded biotechnology companies.

Related Party Transactions

• In 2023, while our Chief Development Officer (CDO) was on leave, we engaged the services of Noriyuki Kasahara, M.D., Ph.D., a member of our Board of Directors, as interim CDO.
• The son of Fariborz Kamal, our President and Chief Operating Officer is employed in our Information Technology department.
• In March 2024, we entered into a research and option agreement with Reignite Therapeutics Inc. (Reignite), which such agreement covers research funding for vector discovery programs at Reignite and grants us an option to acquire such vectors and related intellectual property.
• David Kirn, M.D., our Chief Executive Officer, is President, Executive Chairman of the Board of Directors, and a controlling stockholder of Reignite.

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on, including the election of directors and executive compensation.
• Employees are indirectly impacted through the company's compensation policies and benefit plans.
• The outcome of the votes could influence investor confidence and the company's stock price.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 17, 2025, and announce the voting results within four business days.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, PricewaterhouseCoopers, Say-on-Pay, Corporate Governance, 4D Molecular Therapeutics, Compensation, Audit Committee